Keren Rouvinov
Overview
Explore the profile of Keren Rouvinov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shrem N, Levin D, Rouvinov K, Ben-Arie G, Liberzon I, Hod N
Clin Nucl Med
. 2024 Jul;
49(12):e702-e704.
PMID: 39010310
"Burned-out" testicular tumor is a very rare clinical phenomenon, which refers to the presence of a metastatic germ cell tumor with no clinical findings in the testicle due to spontaneous...
2.
Zohar Y, Sivan B, Mintz I, Hefer B, Rouvinov K, Shrem N, et al.
J Pers Med
. 2024 Feb;
14(2).
PMID: 38392591
Upper tract urothelial carcinoma (UTUC) in a duplex collecting system (DCS) is a relatively uncommon presentation with unclear management guidelines. Herein, we retrospectively reviewed all published cases of DCS with...
3.
Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
Rouvinov K, Mazor G, Kozlener E, Meirovitz A, Shrem N, Abu Saleh O, et al.
J Pers Med
. 2023 Nov;
13(11).
PMID: 38003938
In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI's in penile squamous...
4.
Yakobson A, Rouvinov K, Cohen A, Goldstein I, Abu Saleh O, Solomon A, et al.
J Pers Med
. 2023 Sep;
13(9).
PMID: 37763109
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic approach to diverse malignancies, leading to substantial enhancements in patient prognosis. However, along with their benefits, ICIs also increase the incidence of...
5.
Keizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630724
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol-Modified...
6.
Shalata W, Yakobson A, Cohen A, Goldstein I, Abu Saleh O, Dudnik Y, et al.
Life (Basel)
. 2023 Aug;
13(8).
PMID: 37629514
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and...
7.
Shalata W, Massalha I, Ishay S, Chernomordikova E, Abu Jama A, Rouvinov K, et al.
Life (Basel)
. 2023 Jul;
13(7).
PMID: 37511961
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent...
8.
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, et al.
Front Oncol
. 2023 Jun;
13:1151701.
PMID: 37293597
Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on...
9.
Yusim I, Mazor E, Frumkin E, Jabareen M, Hefer B, Elsaraya N, et al.
Prostate
. 2023 Jun;
83(13):1255-1262.
PMID: 37263774
Background: Targeting biopsy (TBx) of suspicious lesions combined with random systematic biopsy (SBx) improves detection rates of prostate cancer (PCa) during magnetic resonance imaging (MRI)/ultrasound (US) fusion prostate biopsy. However,...
10.
Kaufman B, Abramov O, Ievko A, Apple D, Shlapobersky M, Allon I, et al.
Sci Adv
. 2023 May;
9(21):eadg2809.
PMID: 37235664
Accurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying patients with cancer to ICI treatments. Here, we present a new concept for a bioassay...